论文部分内容阅读
目的:探讨雾化吸入不同剂量布地奈德在小儿哮喘急性发作中的临床价值。方法:53例哮喘急性发作患儿均为本院在2015年6月-2015年12月收治,将其按照给药剂量的不同分为观察组27例和对照组26例,观察组在常规治疗基础上实施大剂量(1.0 mg/次)布地奈德雾化吸入治疗,对照组患儿在常规治疗基础上实施小剂量(0.5 mg/次)布地奈德雾化吸入治疗,对比两组患者临床疗效以及不良反应发生率。结果:观察组治疗后24 h和72 h临床症状评分分别为(4.4±0.6)分和(1.4±0.2)分,不良反应发生率为4.26%;对照组治疗后24 h和治疗后72 h的临床症状评分分别为(6.1±1.5)分和(3.5±0.8)分,不良反应发生率为17.39%。两组患儿治疗后24 h和72 h的临床症状评分以及不良反应发生率的组间比较,差异具有统计学意义(P<0.05)。结论:相较于小剂量布地奈德,大剂量布地奈德雾化吸入治疗小儿哮喘急性发作的临床效果更佳,临床症状缓解较快,且不良反应发生率较低。
Objective: To investigate the clinical value of inhaled budesonide in acute asthma attack in children. Methods: Fifty-three children with acute asthma attack were treated in our hospital from June 2015 to December 2015. The patients were divided into observation group (n = 27) and control group (n = 26) according to different doses. The observation group Based on the implementation of high-dose (1.0 mg / budesonide inhalation therapy, the control group on the basis of conventional treatment of small doses (0.5 mg / budesonide inhalation therapy, compared to the two groups of patients Efficacy and incidence of adverse reactions. Results: The scores of clinical symptoms in observation group at 24 h and 72 h after treatment were (4.4 ± 0.6) and (1.4 ± 0.2) points respectively, and the incidence of adverse reactions was 4.26%. In control group at 24 h and 72 h after treatment Clinical symptom scores were (6.1 ± 1.5) points and (3.5 ± 0.8) points, the incidence of adverse reactions was 17.39%. The scores of clinical symptoms and the incidence of adverse reactions in both groups at 24 and 72 hours after treatment were significantly different (P <0.05). CONCLUSIONS: Compared with low-dose budesonide, high-dose budesonide inhalation is more effective in treating acute asthma attack in children, and the clinical symptoms are relieved quickly and the incidence of adverse reactions is lower.